For Immediate Release

February 6, 2018

Sumitomo Chemical Reports
Consolidated Financial Results
For the Nine Months Ended December 31, 2017
The Sumitomo Chemical Group’s sales for the nine months ended December 31, 2017,
totaled ¥1,621.3 billion, an increase of ¥231.5 billion compared with the same periodof the previous fiscal year. The Group posted operating income of ¥131.1 billion,
ordinary income of ¥171.2 billion and net income attributable to owners of the parentof ¥108.6 billion, all representing year-on-year increases.
The Sumitomo Chemical Group’s financial results by business segment for thenine-month period were as follows.
Petrochemicals & Plastics
Market prices of petrochemical products and synthetic resins rose because of higher
feedstock prices. Market prices of raw materials for synthetic fibers and methyl
methacrylate (MMA) also increased. As a result, the segment’s sales grew by ¥92.2
billion compared with the same period of the previous fiscal year, to ¥506.3 billion.
Operating income increased by ¥20.6 billion, to ¥38.1 billion.
Energy & Functional Materials
Shipments of resorcinol, a raw material for adhesives, and engineering plastics
increased due to a rise in demand. Shipments of separators for lithium-ion secondary
batteries also rose due to production capacity expansion. In addition, the acquisitionof a manufacturer of cathode materials in the previous fiscal year pushed up sales.
As a result, the segment’s sales increased by ¥41.0 billion compared with the same
period of the previous fiscal year, to ¥187.0 billion. Operating income grew by ¥10.0billion, to ¥15.2 billion.
IT-related Chemicals
Although selling prices of touchscreen panels and polarizing film declined,shipments increased due to growth in demand. The weaker yen had a positive effecton sales from overseas subsidiaries in yen terms. As a result, the segment’s sales
increased by ¥16.8 billion compared with the same period of the previous fiscal year,to ¥286.6 billion. Operating income rose by ¥4.4 billion, to ¥13.3 billion.

Health & Crop Sciences
Sales of the feed additive methionine dropped due to lower market prices. Meanwhile,
the acquisition of an Indian agrochemicals company in the previous fiscal year
boosted sales. As a result, the segment’s sales increased by ¥21.9 billion comparedwith the same period of the previous fiscal year, to ¥213.8 billion. Operating income
declined by ¥0.9 billion, to ¥15.7 billion.
Pharmaceuticals
In North America, sales of Latuda® (atypical antipsychotic) and other drugs
increased steadily. In Japan, sales of Trulicity® (type 2 diabetes drug), Aimix®
(anti-hypertension drug) and other drugs rose as well. As a result, the segment’ssales increased by ¥59.7 billion from the same period of the previous fiscal year, to¥389.4 billion. Operating income grew by ¥11.9 billion, to ¥58.0 billion.
OthersIn addition to the above five segments, the Sumitomo Chemical Group engages insupplying electrical power and steam, providing services for the design, engineering,and construction management of chemical plants, providing transport andwarehousing, and conducting materials and environmental analysis. The segment’s
sales came to ¥38.3 billion, almost unchanged from the same period of the previous
fiscal year. Operating income declined by ¥1.0 billion compared with the same periodof the previous fiscal year, to ¥2.7 billion.
Equity in earnings of affiliates increased by ¥14.3 billion compared with the same
period of the previous fiscal year, to ¥40.1 billion. Earnings of Petrochemical
Corporation of Singapore remained strong. Earnings of Rabigh Refining andPetrochemical Company (Petro Rabigh) improved due chiefly to a continued highlevel of capacity utilization and an improvement in oil refining margins.

Summary of Consolidated Results(1) Results of Operations:

Net sales
Operating income
Ordinary income
Income before income taxes
ࠉand non-controlling interests
Net income
Net income attributable tonon-controlling interests
Net income attributable toowners of the parent

Net income per 1,000 shares

Comprehensive income

9 Months ended
December 31, 2017
Yen (Millions)
USD (Thousands)*
1,621,289
14,347,690
131,142
1,160,549
171,240
1,515,398

9 Months ended
December 31, 2016
Yen (Millions)
1,389,802
86,279115,001

173,896148,261

1,538,903
1,312,044

106,953
82,11739,708351,398

26,807

108,553

960,646

55,310Yen
66,429

USD*
588

Yen
33,845

Yen (Millions)
186,789

USD (Thousands)*
1,653,000

Yen (Millions)
76,727

As of December 31, 2017
Yen (Millions)
USD (Thousands)*
3,123,341
27,640,186
1,304,768
11,546,619

As of March 31, 2017
Yen (Millions)
2,862,052
1,162,526

9 Months ended
December 31, 2017
Yen (Millions)
USD (Thousands)*
140,938
1,247,239(113,914)(1,008,088)
20,190178,673
244,984
2,168,000

9 Months ended
December 31, 2016
Yen (Millions)
85,339(168,385)
80,320211,6129 Months ended
December 31, 2017
Yen (Millions)
USD (Thousands)*

9 Months ended
December 31, 2016
Yen (Millions)䚷(2) Financial Position:
Total assets
Total net assets(3) Cash Flows:
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations by䚷䚷䚷Business Segment:
Net sales
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersOperating income
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

506,266
187,003
286,591
213,776
389,383
38,2701,621,289

4,480,230
1,654,894
2,536,204
1,891,823
3,445,867
338,672
14,347,690

414,048
145,989
269,809
191,916
329,728
38,312
1,389,802

38,05815,194
13,33915,69957,992
2,717(11,857)
131,142

336,796
134,460
118,044
138,929
513,204
24,044(104,928)
1,160,549

17,502
5,148
8,919
16,56446,0893,719(11,662)
86,279(Note)
ࠉ *:U.S. dollar amounts are translated from yen, for convenience only, at the rate of䚷¥113.00 = $1 prevailing on December 31, 2017.